US Venture Partners, a venture capital investment firm, led a $73m Series E round in MicroTransponder, a medical device company, with participation from GPG Ventures, Exceller Hunt Ventures, Osage University Partners, Action Potential Venture Capital and The Vertical Group. "MicroTransponder is in a dynamic growth phase, and we are fortunate to have energized investors who are championing our progress toward establishing Vivistim as the gold-standard stroke rehabilitation intervention," Richard Foust, MicroTransponder CEO.